FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2550925093> ?p ?o ?g. }

• W2550925093 abstract "Abstract Abstract 4299 Background Adult T-cell leukemia/lymphoma (ATLL) has a poor prognosis because of its chemo-resistance. Many chemotherapeutic regimens have been created but none of them have shown sufficient results. We proposed allogeneic stem cell transplantation (allo-SCT) for ATLL patients and showed an improved survival rate. However, relapse or progression of ATLL is one of the major limiting factors of survival in post SCT patients. Aims In order to establish a better treatment strategy for poor responders after SCT for ATLL, we analyzed the outcome of relapse or progression cases after allo-SCT. We paid special attention to the graft versus ATLL (GvATLL) effect. Methods There were 37 ATLL patients in which allo-SCT was performed in Imamura Bun-in Hospital (IBH) from June 1998 to April 2009. Twenty-eight cases survived over 100 days after SCT. Sixteen of the 30 patients relapsed. Using data in medical records of IBH, we analyzed transplant characteristics and the outcome of these 17 patients retrospectively. Results Disease status at SCT was CR in 2 patients, 2 PR, 5 SD, and 7 PD. Eight patients received conventional stem cell transplantation (CST) and the other seven patients received reduced-intensity stem cell transplantation (RIST). Fourteen patients in 17 obtained remission (10 CR and 5 PR), but the remaining 2 did not (1 SD and 1 PD) after SCT. The sites of relapse or progression in 17 were skin in 10 patients, 8 peripheral blood, 7 lymph node, 3 central nervous system, and 1 bone. All patients discontinued immunosuppressants after relapse or progression. Eleven patients obtained remission. Especially, in 5 out of 11 patients, remission was obtained only by discontinuation of immunosuppressants (graft-versus-ATLL effect), and the time to remission after discontinuation of immunosuppressants was between 1 to 14 days. Twelve patients were complicated with acute GVHD (grade I-IV). Twelve patients died after SCT. The causes of death were disease progression of ATLL in 5 patients, 3 acute GvHD, 3 infectious complications, and 1 interstitial pneumonia. Four patients who were complicated with acute GvHD survived over 3 years. Discussions Ten patients out of 17 experienced relapse or progression as skin lesion, and 8 patients out of 10 achieved re-remission. It suggests that skin lesion can be a warning sign of ATLL relapse. Since various types of clinical entities, such as ATLL relapse, GvHD, or drug eruption, can manifest as skin lesion after SCT, we strongly recommend to do skin biopsy aggressively to clarify the diagnosis. Ten patients out of 17 achieved re-remission (5 of them achieved only after the discontinuation of immunosuppressant), and 2 patients out of 5 attained long-term survival. This fact raises the possibility that GvATLL effect play a role in controlling exacerbation of ATLL. By focusing on the 5 cases that obtained re-remission only with discontinuation of immunosuppressant, 4 cases showed GvATLL effect prior to GvHD, and one patient experienced fatal grade IV GvHD, respectively. These outcomes suggest that immunosuppressant should be resumed in response to the signs of GvHD deterioration. Relapse/progression cases shows poor survival rate compared with non-relapse ones (60% vs 20% P=0.0028). Although re-remission was highly achieved, this fact suggested that countermeasure against GvHD or re-relapse are indispensable for long-term survival. Summary/conclusions Skin was a major site of relapse or progression after SCT in ATLL patients. A certain number of patients obtained remission only by the discontinuation of immunosuppressants. Four patients survived more than 3 years with their complication of acute GVHD. These results suggest that the GvATLL effect after SCT exists and plays an important role in longer survival for poor responders of post allo-SCT in ATLL patients. Disclosures: No relevant conflicts of interest to declare." @default.
• W2550925093 created "2016-11-30" @default.
• W2550925093 creator A5006183398 @default.
• W2550925093 creator A5007220944 @default.
• W2550925093 creator A5038965321 @default.
• W2550925093 creator A5039679596 @default.
• W2550925093 creator A5084337656 @default.
• W2550925093 creator A5091685979 @default.
• W2550925093 date "2009-11-20" @default.
• W2550925093 modified "2023-09-27" @default.
• W2550925093 title "GvATLL Effect in the Relapse and Progression Cases After Hematopoietic Stem Cell Transplantation (HSCT) for Adult T-Cell Leukemia/Lymphoma (ATLL)." @default.
• W2550925093 doi "https://doi.org/10.1182/blood.v114.22.4299.4299" @default.
• W2550925093 hasPublicationYear "2009" @default.
• W2550925093 type Work @default.
• W2550925093 sameAs 2550925093 @default.
• W2550925093 citedByCount "0" @default.
• W2550925093 crossrefType "journal-article" @default.
• W2550925093 hasAuthorship W2550925093A5006183398 @default.
• W2550925093 hasAuthorship W2550925093A5007220944 @default.
• W2550925093 hasAuthorship W2550925093A5038965321 @default.
• W2550925093 hasAuthorship W2550925093A5039679596 @default.
• W2550925093 hasAuthorship W2550925093A5084337656 @default.
• W2550925093 hasAuthorship W2550925093A5091685979 @default.
• W2550925093 hasConcept C126322002 @default.
• W2550925093 hasConcept C141071460 @default.
• W2550925093 hasConcept C143998085 @default.
• W2550925093 hasConcept C2776694085 @default.
• W2550925093 hasConcept C2777408962 @default.
• W2550925093 hasConcept C2778461978 @default.
• W2550925093 hasConcept C2779338263 @default.
• W2550925093 hasConcept C2779695342 @default.
• W2550925093 hasConcept C28328180 @default.
• W2550925093 hasConcept C2911091166 @default.
• W2550925093 hasConcept C54355233 @default.
• W2550925093 hasConcept C71924100 @default.
• W2550925093 hasConcept C86803240 @default.
• W2550925093 hasConcept C90924648 @default.
• W2550925093 hasConceptScore W2550925093C126322002 @default.
• W2550925093 hasConceptScore W2550925093C141071460 @default.
• W2550925093 hasConceptScore W2550925093C143998085 @default.
• W2550925093 hasConceptScore W2550925093C2776694085 @default.
• W2550925093 hasConceptScore W2550925093C2777408962 @default.
• W2550925093 hasConceptScore W2550925093C2778461978 @default.
• W2550925093 hasConceptScore W2550925093C2779338263 @default.
• W2550925093 hasConceptScore W2550925093C2779695342 @default.
• W2550925093 hasConceptScore W2550925093C28328180 @default.
• W2550925093 hasConceptScore W2550925093C2911091166 @default.
• W2550925093 hasConceptScore W2550925093C54355233 @default.
• W2550925093 hasConceptScore W2550925093C71924100 @default.
• W2550925093 hasConceptScore W2550925093C86803240 @default.
• W2550925093 hasConceptScore W2550925093C90924648 @default.
• W2550925093 hasLocation W25509250931 @default.
• W2550925093 hasOpenAccess W2550925093 @default.
• W2550925093 hasPrimaryLocation W25509250931 @default.
• W2550925093 hasRelatedWork W1495360896 @default.
• W2550925093 hasRelatedWork W1730828399 @default.
• W2550925093 hasRelatedWork W1980809353 @default.
• W2550925093 hasRelatedWork W2006011736 @default.
• W2550925093 hasRelatedWork W2029681044 @default.
• W2550925093 hasRelatedWork W2031541810 @default.
• W2550925093 hasRelatedWork W2253800645 @default.
• W2550925093 hasRelatedWork W2464930671 @default.
• W2550925093 hasRelatedWork W2533407516 @default.
• W2550925093 hasRelatedWork W2554248392 @default.
• W2550925093 hasRelatedWork W2558891317 @default.
• W2550925093 hasRelatedWork W2567528160 @default.
• W2550925093 hasRelatedWork W2576908309 @default.
• W2550925093 hasRelatedWork W2581801010 @default.
• W2550925093 hasRelatedWork W2593246816 @default.
• W2550925093 hasRelatedWork W2595201801 @default.
• W2550925093 hasRelatedWork W2979694624 @default.
• W2550925093 hasRelatedWork W2980219334 @default.
• W2550925093 hasRelatedWork W2980643764 @default.
• W2550925093 hasRelatedWork W3205378762 @default.
• W2550925093 isParatext "false" @default.
• W2550925093 isRetracted "false" @default.
• W2550925093 magId "2550925093" @default.
• W2550925093 workType "article" @default.